SCHEMBL1439724

SCHEMBL1439724

NC(=O)NCCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.63
CA2 P00918 2/20 0.63
CA9 Q16790 2/20 0.63
EPHX1 P07099 1/20 0.61
PLAAT5 Q96KN8 2/20 0.59
PLAAT4 Q9UL19 2/20 0.59
CA1 P00915 1/20 0.59
MMP1 P03956 1/20 0.59
MMP2 P08253 1/20 0.59
MMP3 P08254 1/20 0.59
NPC1 O15118 4/20 0.59
RAB9A P51151 4/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
ALDH1A1 P00352 3/20 0.58
TAAR1 Q96RJ0 2/20 0.58
LMNA P02545 1/20 0.56
GAA P10253 1/20 0.56
HPGD P15428 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
HDAC2 Q92769 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Urea SCHEMBL28195209 0.98 CA12 (0.61) CA12CA2CA9EPHX1PLAAT5
SCHEMBL1953254 0.88 L3MBTL1 (0.68) EPHX1NPC1RAB9AALDH1A1TAAR1
Propylene Glycol SCHEMBL28725243 0.87 KMT2A (0.54) CA12CA2CA9EPHX1PLAAT5
Hydrochloric Acid SCHEMBL27759637 0.86 L3MBTL1 (0.66) EPHX1NPC1RAB9AALDH1A1TAAR1
SCHEMBL1955322 0.86 TRPV1 (0.65) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL1952776 0.85 TRPV1 (0.68) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL1955741 0.85 TRPV1 (0.68) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL1954419 0.85 TRPV1 (0.68) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL1955588 0.85 TRPV1 (0.68) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL1955492 0.85 TRPV1 (0.68) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105263329-B Methods and compositions for weed control 孟山都技术公司 2020-09-18 CN claimed
US-10609930-B2 Methods and compositions for weed control MONSANTO TECHNOLOGY LLC (US) 2020-04-07 US claimed
US-10612019-B2 Methods and compositions for weed control MONSANTO TECHNOLOGY LLC (US) 2020-04-07 US claimed
US-10568328-B2 Methods and compositions for weed control MONSANTO TECHNOLOGY LLC (US) 2020-02-25 US claimed
EP-3604535-A2 METHODS AND COMPOSITIONS FOR WEED CONTROL Monsanto Technology LLC (US) 2020-02-05 EP claimed
EP-3390355-A1 BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF Helsinn Healthcare S.A. (CH) 2018-10-24 EP claimed
WO-2017162390-A1 BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2017-09-28 WO claimed
CN-106458868-A Guanidine compounds and uses thereof 伊谬诺米特医疗有限公司 2017-02-22 CN claimed
CN-105452462-A Methods and compositions for weed control MONSANTO TECHNOLOGY LLC 2016-03-30 CN claimed
US-20160029644-A1 Methods and Compositions for Weed Control MONSATO TECHNOLOGY LLC (US) 2016-02-04 US claimed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US claimed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP claimed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US claimed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO claimed
CN-1369496-A Use of compound with structure similar to L-phenylalanine as medicine to treat skin diseases LU XIAODE (CN) 2002-09-18 CN claimed
EP-0687251-A1 1,3-DIHYDROINDOL-2-ONE DERIVATIVES SUBSTITUTED IN POSITION 3 BY A NITROGEN GROUP AS VASOPRESSIN AND/OR OCYTOCINE AGONISTS AND/OR ANTAGONISTS SANOFI (FR) 1995-12-20 EP claimed
US-5401766-A Hypotensive agents with vasodilation HOECHST AKTIENGESELLSCHAFT (DE) 1995-03-28 US claimed
EP-0344425-B1 N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents WARNER LAMBERT CO (US) 1993-12-08 EP claimed
US-5158959-A Treatment of hypertension HOECHST AKTIENGESELLSCHAFT (DE) 1992-10-27 US claimed
EP-0344425-A2 N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents WARNER-LAMBERT COMPANY (US) 1989-12-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R CA12 1703/4885CA2 1487/4885CA9 1595/4885
US-10609930-B2 Methods and compositions for weed control AS3MT, NOTUM, POLR1C CA12 4365/4885CA2 2145/4885CA9 2313/4885
US-10612019-B2 Methods and compositions for weed control NOTUM, LOXL3, CXXC5 CA12 4076/4885CA2 2793/4885CA9 2181/4885
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R CA12 2821/4885CA2 2236/4885CA9 2912/4885
US-20160029644-A1 Methods and Compositions for Weed Control AS3MT, NOTUM, POLR1C CA12 4365/4885CA2 2145/4885CA9 2313/4885
US-10568328-B2 Methods and compositions for weed control CYC1, PRDX5, CYCS CA12 4207/4885CA2 1676/4885CA9 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.